Sonnet BioTherapeutics（纳斯达克股票代码：SONN）报告季度每股亏损$(1.56)，不及分析师一致预期的$(1.39)，差距为12.23%。较去年同期每股亏损$(2.46)相比，亏损减少36.59%。

以上内容来自Benzinga Earnings专栏，原文如下：

Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.39) by 12.23 percent. This is a 36.59 percent increase over losses of $(2.46) per share from the same period last year.